Reaction
Kidney Enlargement reporting signals
As of the last recalculation, Kidney Enlargement appears in 1,078 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is TOLVAPTAN (PRR 21.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tolvaptan | 16 | 21.6 | 21.6 |
| Doxepin | 11 | 21.2 | 21.2 |
| Lithium Carbonate | 16 | 18.4 | 18.5 |
| Doxepin Hydrochloride | 11 | 17.0 | 17.0 |
| Raltegravir | 13 | 15.4 | 15.4 |
| Pyrazinamide | 7 | 14.5 | 14.5 |
| Micafungin Sodium | 6 | 13.7 | 13.7 |
| Darunavir | 9 | 11.6 | 11.6 |
| Pegaspargase | 7 | 11.1 | 11.1 |
| Paricalcitol | 7 | 9.6 | 9.6 |
| Deferasirox | 11 | 8.1 | 8.1 |
| Blinatumomab | 4 | 7.4 | 7.4 |
| Palivizumab | 3 | 3.8 | 3.8 |